Physician profile
Jacques Denis
NPI 1295262434
$14,017.38
in general payments reported to CMS, 2019-2025
22 companies · $5,430 in 2025
The $5,430 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $47.34 · 2021: $598 · 2022: $826 · 2023: $830 · 2024: $6,049 · 2025: $5,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $10K · Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $10,000.00 |
| Food and Beverage | $2,308.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,028.22 | 2024-2025 | |
| Inari Medical, INC. | $1,714.59 | 2021-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $515.57 | 2023-2025 | |
| Abiomed | $269.17 | 2024-2025 | Impella |
| Glaxosmithkline, LLC. | $248.10 | 2022-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $237.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $157.88 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $154.38 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Amgen INC. | $138.83 | 2020-2025 | Tezspire |
| Galvanize Therapeutics, INC | $127.46 | 2025 | Aliya System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.57 | 2024-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals Lp | $61.89 | 2025 | Fasenra, Tezspire |
| United Therapeutics Corporation | $46.62 | 2024 | Tyvaso |
| Baxter Healthcare | $46.32 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $42.34 | 2023-2024 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $28.27 | 2024 | Arikayce |
| La Jolla Pharmaceutical Company | $27.38 | 2020 | |
| Electromed, INC. | $24.23 | 2024 | Smartvest |
| Bard Peripheral Vascular, INC. | $20.57 | 2021 | |
| Philips North America LLC | $20.39 | 2024 | (Ae4) Secretion Management |
| Mylan Specialty L.P. | $19.65 | 2023 | Yupelri |
| Paratek Pharmaceuticals, INC. | $14.52 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacques Denis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.